SCRIP awards 2012
Novartis awarded two of the prestigious SCRIP Awards for excellence in innovation and R&D
Novartis has been awarded two of the prestigious SCRIP Awards for excellence in innovation and research and development (R&D). The annual awards event celebrates industry achievements in a number of categories and are considered the premier awards for the global biopharmaceuticals industry.
Novartis won the Clinical Advance of the Year for the Company's EXIST-2 study of everolimus for the treatment of tuberous sclerosis. This award exemplifies the value of the Novartis investment in R&D and its ongoing commitment to addressing unmet medical needs.
Recognized as having achieved the Licensing Deal of the Year, Novartis received the award for its agreement with ThromboGenics and Alcon (a Novartis company) for the commercialization of ocriplasmin for vitreomacular adhesion outside the United States. Novartis has been a recipient of SCRIP Awards for the 5th year running.
